At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 17 enrolled
Drug / intervention
Autologous BMMC transplantationcombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Outcomes of Autologous Bone Marrow Mononuclear Stem Cell (BMMC) Transplantation for Children Suffering From Liver Cirrhosis Due to Biliary Atresia After Kasai's Operation: An Open Label Uncontrolled Clinical Trial
Vinmec Research Institute of Stem Cell and Gene Technology·interventional·Posted Mar 16, 2018·Updated Jun 4, 2024
In Brief
A Phase 2 clinical trial evaluating Autologous BMMC transplantation for Liver Cirrhosis, Biliary. Completed, enrolled 17 participants across 2 sites.
Detailed Summary
The aim of this study was to evaluate the safety and effectiveness of autologous bone marrow mononuclear stem cell transplantation for Children Suffering from Liver Cirrhosis Due to Biliary Atresia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Cirrhosis, Biliary
CountriesVietnam
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJan 2017
First PostedMar 2018
Primary CompletionSep 2021
Study CompletionOct 2021
TodayJul 2026
First PostedMar 16, 2018
Enrollment StartJan 2, 2017
Primary CompletionSep 30, 2021
Study CompletionOct 31, 2021
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 8.3 years ago
Interventions
Autologous BMMC transplantationcombination
Stem cell transplantation